Mylan posts quarterly profit compared to year-earlier loss

This post was originally published on this site

The drugmaker reported net earnings of $39.4 million, or 8 cents per share, in the three months ended June 30, compared to a loss of $168.5 million, or 33 cents per share, a year earlier.

Total revenue of the company, whose merger with Pfizer Inc’s (N:PFE) off-patent branded drugs unit has been delayed by the pandemic, fell to $2.73 billion from $2.85 billion.